Role of Cyclooxygenase-2 Inhibitors in Postoperative Pain Management
Anesthesiology Clinics of North America, ISSN: 0889-8537, Vol: 23, Issue: 1, Page: 49-72
2005
- 28Citations
- 58Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations28
- Citation Indexes28
- 28
- CrossRef21
- Captures58
- Readers58
- 58
Review Description
COX-2 inhibitors represent a significant therapeutic development because of their improved side-effect profile compared with nonselective NSAIDs [81]. Although the analgesic efficacy of the COX-2 inhibitors is similar to that of nonselective NSAIDs, the use of COX-2 inhibitors in the perioperative period is associated with several potential advantages (Box 1). Because of the lack of antiplatelet effects, the COX-2 inhibitor therapy may be continued throughout the perioperative period thus avoiding an exacerbation of postoperative pain. This may be important because the intensity of preoperative pain has been shown to correlate directly with the severity of postoperative pain and opioid requirements [171]. However, questions remain regarding the use of COX-2 inhibitors, such as the restriction of their use to patients at high risk for complications, the impact on postoperative outcomes [172], adverse events [173], cost effectiveness [174], effectiveness compared with nonselective NSAIDs plus prostaglandin replacement or acid reduction therapy, efficacy compared with and in combination with other analgesics [175], and safety in patients also taking aspirin for platelet inhibition [176,177]. Future studies as well as post-marketing surveillance should provide more information regarding the safety of COX-2-specific inhibitors, particularly in high-risk populations. © 2005 Elsevier Inc. All rights reserved.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0889853704001257; http://dx.doi.org/10.1016/j.atc.2004.11.011; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=14844310403&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/15763411; https://linkinghub.elsevier.com/retrieve/pii/S0889853704001257; https://dx.doi.org/10.1016/j.atc.2004.11.011
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know